When the mind will not quiet, relief means more than a score on a questionnaire. For someone living with anxiety, depression, persistent stress or panic episodes, it may mean being able to take a breath, sleep through the night, participate in a conversation or feel present with the people they love.
That lived reality is increasingly part of the scientific conversation about cannabis and mental health. Researchers are studying cannabidiol (CBD), tetrahydrocannabinol (THC), different cannabinoid ratios, medical cannabis patients, and the changes people report in everyday life.
This Mandi Cruz Media research feature brings together eight primary research publications and our complete 12-slide visual series. It examines what patients reported, what researchers measured, and why cannabinoid formulation and individual context matter.
At a glance: What the studies found
- 345 adults over 30 days: In a 2026 diary study, reported anxiety changes differed among THC-dominant, CBD-dominant and balanced THC:CBD flower.
- 300 adults over four weeks: CBD-dominant flower was associated with lower anxiety scores than THC-dominant flower in a 2024 study.
- 302 UK anxiety patients: Of the 249 assessed at one month, 58.2% had a change of at least four points on a standard anxiety questionnaire.
- 33 Maryland patients: A six-month observational study recorded declines in patient-reported anxiety and depression after medical cannabis initiation.
- 698 depression patients: A UK registry study tracked symptom and quality-of-life measures at intervals extending to two years.
- 11,953 real-world sessions: A symptom-tracking study recorded average immediate perceived changes in anxiety, stress and depression.
- Nine Australian patients: Detailed interviews highlighted emotional regulation, sleep, relationships, daily functioning and experiences with panic.
- 24 people with social anxiety: A randomized, placebo-controlled CBD experiment observed reduced anxiety and discomfort during a simulated public-speaking task.
1. Anxiety, cannabinoid profile and 345 adults tracked for 30 days
A 2026 study in the International Journal of Environmental Research and Public Health followed 345 adults who wanted to use cannabis for anxiety relief. Participants used flower or edible products, and daily reports tracked anxiety alongside use for 30 days.
Among the flower conditions, the researchers reported average within-day anxiety reductions of 39.5% with THC+CBD flower, 34.8% with CBD-dominant flower and 7.8% with THC-dominant flower. This is a comparison of reported anxiety changes associated with product use—not a claim that each product has the same effect on every person.
The study also examined patterns over time: CBD-dominant edibles were associated with lower anxiety across the month. Together, these findings invite a more useful question than simply “Does cannabis help anxiety?”: Which cannabinoid profile, which format, and which kind of response are we measuring?
2. CBD-dominant flower: less immediate tension, lower anxiety scores
In Bidwell and colleagues’ 2024 study, researchers analyzed 300 adults: 258 people who used cannabis flower and 42 who did not use cannabis. The cannabis participants were assigned to THC-dominant, CBD-dominant, or balanced THC+CBD flower groups.
Over four weeks, the study used validated mood and anxiety measures, including the Depression Anxiety Stress Scales (DASS). After accounting for use frequency, CBD-dominant flower was associated with lower anxiety scores than THC-dominant flower. Immediately after use, the CBD-dominant group also reported less tension and paranoia on standardized mood measures.
One of the strengths of this study is that it considered both the immediate experience and changes over several weeks. That distinction matters for people who describe short-term calm but also want to understand their day-to-day baseline.
3. Generalized anxiety: 302 medical cannabis patients and measurable change
Researchers examining the UK Medical Cannabis Registry in 2023 included 302 patients with baseline anxiety assessments who were prescribed cannabis-based medicinal products. They assessed changes at one, three and six months using the GAD-7 anxiety scale, as well as sleep and quality-of-life measures.
Of the 249 patients assessed at one month, 145 (58.2%) had a decrease of at least four points on the GAD-7—an established threshold for a minimally clinically important change. The proportions meeting that four-point threshold were 55% at three months and 43.6% at six months among participants assessed at those points.
Sleep and health-related quality-of-life scores also improved at the study’s follow-up points. It is important to read the statistic precisely: 58.2% refers to participants with a meaningful four-point score reduction at one month; it is not a claim that 58.2% experienced remission.
4. Research from Maryland: anxiety and depression over six months
Maryland is not just part of the cannabis policy conversation—it is part of the research landscape. A 2025 Johns Hopkins-affiliated prospective study followed 33 adults in Maryland who were beginning medical cannabis use and had clinically significant anxiety and/or depression symptoms.
Participants completed repeated in-the-moment reports as well as standardized questionnaires at baseline and at one, three and six months. Anxiety and depression scores declined significantly from baseline, and mean scores fell below the study’s clinically significant threshold by month three. Average scores remained lower than baseline at six months.
Most participants selected THC-dominant products. Because this was a prospective observational cohort in which participants chose their products, the results describe measured changes among people initiating treatment; they do not establish that one cannabinoid or formulation caused the improvement.
For Maryland patients, educators and providers, this is especially meaningful: the study followed people in our state through the transition from considering medical cannabis to documenting their own outcomes.
5. Depression research: 698 patients followed for up to two years
A 2026 analysis of the UK Medical Cannabis Registry focused on 698 patients receiving cannabis-based medicinal products for depression. Researchers collected patient-reported measures at baseline and at one, three, six, 12, 18 and 24 months.
Rather than relying on a single yes-or-no question, the study tracked multiple dimensions: depression severity (PHQ-9), anxiety (GAD-7), sleep quality, health-related quality of life and patients’ impressions of change. The reported group-level changes across follow-ups were encouraging, with improved depression measures and other patient-reported outcomes.
That extended timeline distinguishes this analysis from studies focused only on how someone feels shortly after consuming a product. It allows researchers to examine how reported outcomes evolve—while retaining the distinction between registry associations and conclusions from randomized controlled trials.
6. Stress reduction in 11,953 real-world sessions
For many people, stress is immediate and physical: racing thoughts, muscular tension or feeling emotionally overloaded. A 2018 naturalistic study by Cuttler and colleagues used a cannabis symptom-tracking app to analyze 11,953 self-reported sessions.
Those sessions consisted of 5,085 anxiety entries, 3,717 stress entries and 3,151 depression entries. Across the tracked sessions, users perceived average 58% immediate reductions in anxiety and stress and a 50% immediate reduction in depression symptoms following cannabis use.
The wording here is intentional: these are perceived symptom changes immediately following individual sessions, not clinical remission rates or evidence that the same changes necessarily persist months later. They nevertheless capture a large volume of real-world experiences that matter when designing future research.
7. Panic episodes and emotional control: what patients actually describe
Numbers tell one part of the story. A 2026 Australian qualitative study followed the experiences of nine adults prescribed medical cannabis for anxiety disorders through interviews and diary entries.
Participants described feeling more able to recognize and manage their anxiety, engaging with coping techniques such as breathing and reframing thoughts, and navigating moments of panic with a greater sense of agency. The researchers also heard about changes in sleep, relationships, motivation and participation in everyday activities.
Qualitative research is not designed to produce a treatment success percentage. Its value is different: it can show what “improvement” means to the person living through it, including shifts that standardized questionnaires might not fully capture.
8. A randomized CBD experiment during public speaking
One frequently cited controlled experiment comes from Bergamaschi and colleagues (2011). In a randomized, double-blind design, 24 treatment-naïve people with social anxiety disorder received either 600 mg oral CBD (12 participants) or placebo (12 participants) before a simulated public-speaking task.
Compared with placebo, the CBD group showed less self-reported anxiety, cognitive impairment and discomfort related to the speaking challenge. This is a different kind of evidence from an app diary or registry: it directly compares an assigned treatment with a placebo under controlled experimental conditions.
It also studied a specific oral CBD dose and a specific anxiety-provoking situation. Those details are essential when interpreting what the experiment can—and cannot—tell us about other products, doses or anxiety experiences.
9. The cannabinoid profile matters
Not all cannabis experiences are the same. Recent studies help explain why it is misleading to treat every product labeled “cannabis” as interchangeable.
- THC-dominant: Products with more THC and relatively little CBD.
- CBD-dominant: Products with more CBD and relatively little THC.
- Balanced THC:CBD: Products combining meaningful amounts of both cannabinoids.
The 2026 daily-diary study and 2024 flower comparison reported different anxiety-related patterns across these categories. The Maryland study, meanwhile, observed changes among patients who largely selected THC-dominant products. These findings are not contradictory when we recognize differences in population, product, outcome measure and timeline.
Researchers are increasingly asking about cannabinoid composition, formulation, route of administration, frequency of use and individual response. For foundational context, see our guides to cannabis consumption methods and timing and the endocannabinoid system.
10. Beyond symptom scores: relief is more than a number
A meaningful mental-health outcome can take many forms. In the 2026 qualitative interviews, participants talked about experiences that extend beyond a questionnaire:
- Feeling less emotionally overwhelmed
- Greater confidence in managing anxiety
- More restorative sleep
- Better engagement with family, friends and relationships
- Improved motivation, daily functioning and willingness to participate in life
These accounts do not replace standardized outcomes; they add context to them. If a person reports a lower anxiety score, what changed in their day? Could they sleep? Leave the house? Enjoy dinner? Reconnect with someone they love?
These are the questions that can help research remain connected to the lives it is meant to describe. Explore our related article on cannabis and sleep for a closer look at the nighttime experience.
11. What the research means—and where science goes next
The full picture includes controlled CBD experiments, prospective cohorts, daily diaries, clinical registries and patient interviews. Each design contributes a different piece:
- Controlled experiments examine a defined intervention under comparison conditions.
- Daily diaries and symptom-tracking apps document changes reported around use in everyday settings.
- Prospective cohorts and registries follow patients across weeks, months and sometimes years.
- Qualitative interviews explore how patients experience anxiety, coping and quality of life.
Taken together, the results are encouraging and worthy of continued scientific attention. Larger, carefully controlled trials can help clarify which cannabinoids, formulations, doses, delivery methods and patient groups are most likely to benefit—and which outcomes remain consistent over time.
Real people. Measurable outcomes. Science moving forward.
Frequently asked questions about cannabis and mental health research
What does research say about CBD and anxiety?
The 2011 placebo-controlled social-anxiety experiment observed reduced anxiety during a simulated speech task after a single oral CBD dose. A larger 2024 flower study associated CBD-dominant cannabis with less immediate tension and lower four-week anxiety scores than THC-dominant flower. Those studies examine different formulations and research settings.
Have researchers studied cannabis for depression over time?
Yes. A 2026 UK registry case series included 698 patients with depression and assessed patient-reported depression, anxiety, sleep and quality-of-life measures at intervals extending to 24 months. A separate Maryland cohort of 33 patients followed anxiety and depression outcomes for six months.
Do symptom-tracking results show long-term stress relief?
The 11,953-session study documented immediate perceived changes after use. Longitudinal effects require studies that follow participants over time; that is why the 30-day diaries, Maryland six-month cohort and longer UK registries are useful complementary evidence.
Why do THC:CBD ratios and methods of consumption matter?
Different cannabinoid profiles and methods can create different exposure patterns. Research increasingly examines THC-dominant, CBD-dominant and balanced products separately, along with timing, frequency and individual variation. Learn more in our methods of consumption guide.
Original peer-reviewed research and source links
- 2026: Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products. International Journal of Environmental Research and Public Health. 345 adults; 30 days.
- Bidwell et al. (2024): Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower. Cannabis and Cannabinoid Research. 300 adults; four weeks.
- 2023: Clinical outcome data of anxiety patients treated with cannabis-based medicinal products in the United Kingdom. Psychopharmacology. 302 patients.
- Wolinsky et al. (2025): Acute and Chronic Effects of Medicinal Cannabis Use on Anxiety and Depression in a Prospective Cohort of Patients New to Cannabis. Journal of Affective Disorders. Maryland; 33 patients.
- 2026: UK Medical Cannabis Registry: A two-year case series of clinical outcomes in depression. Journal of Affective Disorders. 698 patients.
- Cuttler et al. (2018): A naturalistic examination of the perceived effects of cannabis on negative affect. Journal of Affective Disorders. 11,953 tracked sessions.
- Roberts et al. (2026): Beyond symptom change: a qualitative descriptive study of reported quality of life experiences among adults prescribed medicinal cannabis for anxiety disorders. International Journal of Clinical Pharmacy. Nine interviews/diaries.
- Bergamaschi et al. (2011): Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 24 randomized participants.
About the author: Mandi Cruz, M.S., earned a Master of Science in Medical Cannabis Science and Therapeutics from the University of Maryland School of Pharmacy. Through Mandi Cruz Media, she translates cannabinoid research into accessible, science-led education for patients and curious consumers.
Mandi Cruz Media · Science Meets Stardust™ · Explore our education, guides and consultations.
0 comments